A Phase 1 interventional study of Anifrolumab SC injection (300mg) and Anifrolumab IV infusion (300mg) in Safety, Pharmacokinetics and Healthy Subjects, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-26.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy subjects
This is a Phase I placebo-controlled study to assess the pharmacokinetics, safety and tolerability of 2 doses of anifrolumab via the subcutaneous (SC) route of administration and 1 dose of anifrolumab via intravenous (IV) route in healthy subjects
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Previous receipt of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
300 mg single dose anifrolumab delivered as 2 separate 1 mL SC injections administered serially
Drug: Anifrolumab SC injection (300mg)
300 mg single dose anifrolumab delivered as an IV infusion over 30 minutes
Drug: Anifrolumab IV infusion (300mg)
600 mg single dose anifrolumab or placebo delivered as 4 mL SC by infusion pump
Drug: Anifrolumab SC infusion (600mg)
300 mg single dose placebo delivered as 2 separate 1 mL SC injections administered serially
Drug: Anifrolumab placebo SC injection (300mg)
300 mg single dose placebo delivered as an IV infusion over 30 minutes
Drug: Anifrolumab placebo IV infusion (300mg)
600 mg single dose placebo delivered as 4 mL SC by infusion pump
Drug: Anifrolumab placebo SC infusion (600mg)
300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1
300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1
600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1
300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1
600mg of placebo delivered as an IV infusion over 30 minutes on Day 1
600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1
Pharmacokinetics: Observed Maximum Serum Concentration (Cmax) Following Single Dose of Anifrolumab.
To evaluate Cmax of anifrolumab after single administration of two doses subcutaneously and one dose intravenously. Up to 13 blood samples were collected in total.
Time frame: On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days
Pharmacokinetics: Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Following Single Dose of Anifrolumab
To evaluate AUC(0-t) of anifrolumab after single administration of two doses subcutaneously and one dose intravenously Up to 13 blood samples were collected in total.
Time frame: On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days
Pharmacokinetics: Area Under Serum Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) Following Single Dose of Anifrolumab
To evaluate AUC of anifrolumab after single administration of two doses subcutaneously and one dose intravenously. Up to 13 blood samples were collected in total.
Time frame: On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days
Safety: Number of Participants With Adverse Events (AEs)
To assess the safety and tolerability of single doses of anifrolumab
Time frame: From screening to final follow-up visit, up to 16 weeks
Safety: Summary of Local Injection Site Pain (SC Cohorts) Assessed in Participants
Local injection site pain was assessed using a 100 mm participant rated Visual Analog Scale (VAS 0mm - 100mm ungraduated scale, where 0 = "no pain" to 100 = "worst imaginable pain"). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average VAS score (0mm-100mm) of the two injection sites were reported.
Time frame: Immediately after dosing, at 10, 20 minutes and 1 hour after injection
Safety: Summary of Local Injection Site Pruritus (SC Cohorts) Assessed in Participants
Local injection site pruritus was assessed using a 100 mm participant rated Visual Analog Scale (VAS 0mm - 100mm ungraduated scale, where 0 = "no itching" to 100 = "worst imaginable itching"). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average VAS score (0mm-100mm) of the two injection sites were reported.
Time frame: Immediately after dosing, at 10, 20 minutes and 1 hour after injection
Safety: Summary of Erythema Injection Site Reaction (SC Cohorts) Assessed in Participants
Erythema was measured as the largest diameter across the needle site on the skin in millimetres (mm). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average of the two injection site diameters (mm) were reported.
Time frame: Immediately after dosing, at 10, 20 minutes and 1 hour after injection
Safety: Summary of the Induration Injection Site Reaction (SC Cohorts) Assessed in Participants
Induration was measured as the largest diameter across the needle site on the skin in millimetres (mm). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average of the two injection site diameters (mm) were reported.
Time frame: Immediately after dosing, at 10, 20 minutes and 1 hour after injection
Evaluation of Immunogenicity of Anifrolumab IV Infusions and SC Injections by the Measurement of Anti-drug Antibody (ADA).
Immunogenicity was assessed in all groups by the presence or absence of ADA, which was determined in serum samples using validated bioanalytical methods. The reported results are based on the confirmatory assay (positive/negative) of the ADA. The number of participants with positive, negative and missing results are reported for each time point using the safety analysis set.
Time frame: Pre-dose and at Days 5 and Day 29, up to 85 days
This study was conducted at the PAREXEL Early Phase Clinical Unit Baltimore, 3001 S. Hanover St. Baltimore, MD 21225 United States of America
| Milestone | Anifrolumab 300 mg SC Injections | Anifrolumab 300 mg IV Infusion | Anifrolumab 600 mg SC Infusion | Pooled Placebo |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 12 |
| Completed | 6 | 6 | 5 | 11 |
| Not completed | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 |
To evaluate Cmax of anifrolumab after single administration of two doses subcutaneously and one dose intravenously. Up to 13 blood samples were collected in total.
| ug/mL | Anifrolumab 300 mg SC Injections | Anifrolumab 300 mg IV Infusion | Anifrolumab 600 mg SC Infusion |
|---|---|---|---|
| Pharmacokinetics: Observed Maximum Serum Concentration (Cmax) Following Single Dose of Anifrolumab. | 36.22 ± 11.63 | 82.44 ± 13.16 | 63.86 ± 20.45 |
To evaluate AUC(0-t) of anifrolumab after single administration of two doses subcutaneously and one dose intravenously Up to 13 blood samples were collected in total.
| day*μg/mL | Anifrolumab 300 mg SC Injections | Anifrolumab 300 mg IV Infusion | Anifrolumab 600 mg SC Infusion |
|---|---|---|---|
| Pharmacokinetics: Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Following Single Dose of Anifrolumab | 769.1 ± 336.9 | 902.9 ± 175.8 | 1639 ± 557.7 |
To evaluate AUC of anifrolumab after single administration of two doses subcutaneously and one dose intravenously. Up to 13 blood samples were collected in total.
| day*μg/mL | Anifrolumab 300 mg SC Injections | Anifrolumab 300 mg IV Infusion | Anifrolumab 600 mg SC Infusion |
|---|---|---|---|
| Pharmacokinetics: Area Under Serum Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) Following Single Dose of Anifrolumab | 784.6 ± 330.6 | 906.5 ± 174.9 | 1828 ± 679.8 |
To assess the safety and tolerability of single doses of anifrolumab
| Participants | Anifrolumab 300 mg SC Injections | Anifrolumab 300 mg IV Infusion | Anifrolumab 600 mg SC Infusion | Pooled Placebo | Placebo 300 mg Anifrolumab SC | Placebo 600 mg Anifrolumab SC | Placebo 300 mg Anifrolumab IV | All Anifrolumab Participants |
|---|---|---|---|---|---|---|---|---|
| Safety: Number of Participants With Adverse Events (AEs) | 3 | 2 | 4 | 4 | 1 | 2 | 1 | 9 |
Local injection site pain was assessed using a 100 mm participant rated Visual Analog Scale (VAS 0mm - 100mm ungraduated scale, where 0 = "no pain" to 100 = "worst imaginable pain"). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average VAS score (0mm-100mm) of the two injection sites were reported.
| Millimeter | Anifrolumab 300 mg SC Injections | Anifrolumab 600 mg SC Infusion | Placebo 300 mg Anifrolumab SC | Placebo 600 mg Anifrolumab SC |
|---|---|---|---|---|
| Immediately after dosing | 1.2 ± 2.21 | 0.0 ± 0.00 | 8.0 ± 13.69 | 0.0 ± 0.00 |
| 10 min after injection | 0.5 ± 0.63 | 0.0 ± 0.00 | 0.5 ± 1.00 | 0.0 ± 0.00 |
| 20 min after injection | 0.3 ± 0.42 | 0.0 ± 0.00 | 0.4 ± 0.75 | 0.3 ± 0.50 |
| 1 hour after injection | 0.2 ± 0.41 | 0.0 ± 0.00 | 0.3 ± 0.50 | 0.0 ± 0.00 |
Local injection site pruritus was assessed using a 100 mm participant rated Visual Analog Scale (VAS 0mm - 100mm ungraduated scale, where 0 = "no itching" to 100 = "worst imaginable itching"). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average VAS score (0mm-100mm) of the two injection sites were reported.
| Millimeter | Anifrolumab 300 mg SC Injections | Anifrolumab 600 mg SC Infusion | Placebo 300 mg Anifrolumab SC | Placebo 600 mg Anifrolumab SC |
|---|---|---|---|---|
| Immediately after dosing | 1.3 ± 2.60 | 14.0 ± 20.29 | 1.3 ± 1.66 | 0.8 ± 0.96 |
| 10 min after injection | 0.7 ± 1.21 | 6.3 ± 14.56 | 0.6 ± 1.25 | 0.0 ± 0.00 |
| 20 min after injection | 0.3 ± 0.52 | 1.5 ± 3.67 | 0.5 ± 1.00 | 0.3 ± 0.50 |
| 1 hour after injection | 0.1 ± 0.20 | 0.0 ± 0.00 | 0.4 ± 0.75 | 0.0 ± 0.00 |
Erythema was measured as the largest diameter across the needle site on the skin in millimetres (mm). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average of the two injection site diameters (mm) were reported.
| Millimeter | Anifrolumab 300 mg SC Injections | Anifrolumab 600 mg SC Infusion | Placebo 300mg SC Injection | Placebo 600 mg SC Injection |
|---|---|---|---|---|
| Immediately after dosing | 0.3 ± 0.42 | 17.0 ± 19.75 | 11.5 ± 14.62 | 20.0 ± 13.54 |
| 10 minutes after injection | 2.0 ± 4.18 | 17.5 ± 21.39 | 5.1 ± 9.59 | 18.0 ± 14.99 |
| 20 minute after injection | 2.7 ± 4.14 | 16.6 ± 20.81 | 5.5 ± 9.11 | 26.0 ± 18.55 |
| 1 hour after injection | 0.3 ± 0.52 | 2.5 ± 6.12 | 0.3 ± 0.50 | 10.0 ± 14.14 |
Immunogenicity was assessed in all groups by the presence or absence of ADA, which was determined in serum samples using validated bioanalytical methods. The reported results are based on the confirmatory assay (positive/negative) of the ADA. The number of participants with positive, negative and missing results are reported for each time point using the safety analysis set.
| Participants | Anifrolumab 300 mg SC Injections | Anifrolumab 300 mg IV Infusion | Anifrolumab 600 mg SC Infusion | Pooled Placebo | All Subjects |
|---|---|---|---|---|---|
| Day 1, pre-dose (positive) | 0 | 0 | 0 | 0 | 0 |
| Day 1, pre-dose (negative) | 6 | 6 | 6 | 12 | 30 |
| Day 1, pre-dose (missing) | 0 | 0 | 0 | 0 | 0 |
| Day 5 (positive) | 0 | 0 | 0 | 0 | 0 |
| Day 5 (negative) | 6 | 6 | 6 | 12 | 30 |
| Day 5 (missing) | 0 | 0 | 0 | 0 | 0 |
| Day 29 (positive) | 0 | 0 | 0 | 0 | 0 |
| Day 29 (negative) | 6 | 6 | 5 | 11 | 28 |
| Day 29 (missing) | 0 | 0 | 1 | 1 | 2 |
| Day 85 (positive) | 0 | 1 | 0 | 0 | 1 |
| Day 85 (negative) | 6 | 5 | 5 | 11 | 27 |
| Day 85 (missing) | 0 | 0 | 1 | 1 | 2 |
Induration was measured as the largest diameter across the needle site on the skin in millimetres (mm). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average of the two injection site diameters (mm) were reported.
| Millimeter | Anifrolumab 300 mg SC Injections | Anifrolumab 600 mg SC Infusion | Placebo 300mg SC Injection | Placebo 600 mg Anifrolumab SC |
|---|---|---|---|---|
| Immediately after dosing | 4.2 ± 10.21 | 22.5 ± 13.69 | 0.0 ± 0.00 | 12.5 ± 15.00 |
| 10 minutes after injection | 0.8 ± 2.04 | 17.3 ± 12.39 | 0.0 ± 0.00 | 16.5 ± 19.21 |
| 20 minute after injection | 0.1 ± 0.20 | 14.1 ± 11.41 | 0.1 ± 0.25 | 8.0 ± 16.00 |
| 1 hour after injection | 0.0 ± 0.00 | 11.7 ± 13.29 | 0.0 ± 0.00 | 12.5 ± 25.00 |
Collected over From screening to final follow-up visit, up to 16 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Anifrolumab 300 mg SC Injections | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Anifrolumab 300 mg IV Infusion | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Placebo 300 mg Anifrolumab SC | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Placebo 300 mg IV Infusion | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Placebo 600 mg Anifrolumab (SC) | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Anifrolumab 600 mg SC Infusion | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Pooled Placebo | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| All Anifrolumab Subjects | 0/18 (0%) | 0/18 (0%) | 9/18 (50%) |
| Event | Anifrolumab 300 mg SC Injections | Anifrolumab 300 mg IV Infusion | Placebo 300 mg Anifrolumab SC | Placebo 300 mg IV Infusion | Placebo 600 mg Anifrolumab (SC) | Anifrolumab 600 mg SC Infusion | Pooled Placebo | All Anifrolumab Subjects |
|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/6 | 1/6 | 0/4 | 0/4 | 0/4 | 0/6 | 0/12 | 3/18 |
| Dry throatRespiratory, thoracic and mediastinal disorders | 0/6 | 2/6 | 0/4 | 0/4 | 0/4 | 0/6 | 0/12 | 2/18 |
| Oral herpesInfections and infestations | 0/6 | 0/6 | 0/4 | 1/4 | 0/4 | 0/6 | 1/12 | 0/18 |
| Peripheral swellingGeneral disorders | 0/6 | 0/6 | 1/4 | 0/4 | 0/4 | 0/6 | 1/12 | 0/18 |
| HeadacheNervous system disorders | 1/6 | 0/6 | 0/4 | 0/4 | 1/4 | 0/6 | 1/12 | 1/18 |
| Menstrual disorderReproductive system and breast disorders | 1/4 | 0/1 | 0/1 | 0/2 | 0/1 | 0/2 | 0/4 | 1/7 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 0/4 | 0/4 | 1/4 | 0/6 | 1/12 | 0/18 |
| Tooth abscessInfections and infestations | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 1/6 | 0/12 | 1/18 |
| Tinea pedisInfections and infestations | 0/6 | 0/6 | 0/4 | 0/4 | 0/4 | 1/6 | 0/12 | 1/18 |
| Abdominal discomfortGastrointestinal disorders | 1/6 | 0/6 | 0/4 | 0/4 | 0/4 | 0/6 | 0/12 | 1/18 |
Thirty healthy male and female subjects were included in this study, 6 subjects per anifrolumab treatment (300 mg anifrolumab SC, 300 mg anifrolumab IV, 600 mg anifrolumab SC) and 12 subjects for placebo treatment.
| Age, Continuous(Years) | Anifrolumab 300 mg SC Injections | Anifrolumab 300 mg IV Infusion | Anifrolumab 600 mg SC Infusion | Pooled Placebo | Total |
|---|---|---|---|---|---|
| Mean | 27.5 ± 6.89 | 29.7 ± 7.97 | 26.3 ± 6.65 | 38.4 ± 12.26 | 32.1 ± 10.62 |
| Sex/Gender, Customized(Count of participants) | Anifrolumab 300 mg SC Injections | Anifrolumab 300 mg IV Infusion | Anifrolumab 600 mg SC Infusion | Pooled Placebo | Total |
|---|---|---|---|---|---|
| Female | 4 | 1 | 2 | 4 | 11 |
| Male | 2 | 5 | 4 | 8 | 19 |
Ran from Nov 2015 to primary completion in May 2016, 6 months.
Results were first posted in Feb 2019, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anifrolumab